Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages

  Clausen, L N ^a,b   Weis, N ^a,b   Astvad, K ^a   Schonning K ^a   Fenger, M ^a,b   Krarup, H ^c   Bukh, J ^a,b   Benfield, T ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

HCV genotype; Hepatitis C virus; Single nucleotide polymorphisms; Spontaneous clearance

Indexed keywords

INTERLEUKIN 28B;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; LIVER FUNCTION; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ADULT; FEMALE; GENE FREQUENCY; HAPLOTYPES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79952655262     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01392.x     Document Type: Article

References (40)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52. (Pubitemid 32634271)
2. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 2002; 359: 1478-1483. (Pubitemid 34457766)
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-S29. (Pubitemid 35253460)
4. Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology 2009; 137: 795-814.
5. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874. (Pubitemid 39038423)
6. Martin MP, Carrington M. Immunogenetics of viral infections. Curr Opin Immunol 2005; 17: 510-516. (Pubitemid 41207955)
7. Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun 2007; 8: 181-192. (Pubitemid 46672051)
8. Thio CL, Gao X, Goedert JJ et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792-4797.
9. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354: 2119-2124.
10. Klenerman P, Kim A. HCV-HIV coinfection: simple messages from a complex disease. PLoS Med 2007; 4: e240.
11. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233. (Pubitemid 29181642)
12. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456. (Pubitemid 30484478)
13. Martell M, Esteban JI, Quer J et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-3229.
14. Barrett S, Ryan E, Crowe J. Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999; 30: 979-983. (Pubitemid 29278739)
15. Fanning LJ, Levis J, Kenny-Walsh E, Whelton M, O'Sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 2001; 33: 224-230. (Pubitemid 32016906)
16. McKiernan SM, Hagan R, Curry M et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004; 40: 108-114. (Pubitemid 38877575)
17. Erickson AL, Kimura Y, Igarashi S et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883-895. (Pubitemid 34075370)
18. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77. (Pubitemid 36109115)
19. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
20. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
21. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
22. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
23. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
24. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
25. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
26. Weis N, Lindhardt BO, Kronborg G et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42: 1481-1487.
27. Krarup HB, Drewes AM, Madsen PH. A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 1998; 58: 415-422. (Pubitemid 28489470)
28. Gottwein JM, Scheel TK, Hoegh AM et al. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007; 133: 1614-1626. (Pubitemid 350029736)
29. Pittaluga F, Allice T, Abate ML et al. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol 2008; 80: 254-260.
30. Krarup HB, Moller JM, Christensen PB et al. Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 2000; 7: 435-439.
31. Murphy DG, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. J Clin Microbiol 2007; 45: 1102-1112. (Pubitemid 46626471)
32. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21: 379-384. (Pubitemid 40246609)
33. Nijman IJ, Kuipers S, Verheul M, Guryev V, Cuppen E. A genome-wide SNP panel for mapping and association studies in the rat. BMC Genomics 2008; 9: 95.
34. R: A Language and Environment for Statistical Computing [computer program]. R Foundation for Statistical Computing, Vienna, Austria; 2010.
35. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76: 449-462. (Pubitemid 40250525)
36. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007; 179: 3434-3442.
37. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
38. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034-7039. (Pubitemid 351754525)
39. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655-661. (Pubitemid 26145477)
40. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 3274-3277. (Pubitemid 27505758)